2seventy bio, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cambridge, mass.--(business wire)--2seventy bio, inc. (nasdaq: tsvt), announced today that eli casdin, chief investment officer, and founder of casdin capital, and charles newton, chief financial officer, lyell immunopharma, have been appointed as new independent members of the company's board of directors (the “board”), effective immediately. casdin capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. “we are pleased to welcome eli and charlie to the 2seventy bo.

Cambridge, mass.--(business wire)-- #tsvt--2seventy bio, inc. (nasdaq: tsvt), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended december 31, 2023. “in the past weeks and months, 2seventy has made significant changes to our business and cost structure designed to optimize our ability to unlock value for abecma,” said chip baird, incoming ceo. “while abecma experienced continued competitive headwinds in the fo.

Cambridge, mass.--(business wire)-- #tsvt--2seventy bio, inc. (nasdaq: tsvt) will announce its fourth quarter and full year 2023 financial results on tuesday, march 5, 2024. a conference call and webcast will be held at 8:00 a.m. et. members of the management team will also be presenting at the following upcoming investor conferences: td cowen 44th annual healthcare conference in boston, ma on wednesday, march 6, 2024 at 2:10 p.m. et leerink partners global biopharma conference in miami, fl on wednesda.

Cambridge, mass.--(business wire)-- #tsvt--2seventy bio, inc. (nasdaq: tsvt), announced today that members of the management team will present at the following upcoming investor conferences: guggenheim healthcare talks 6th annual biotechnology conference, the st. regis new york, fireside chat on thursday, february 8th at 1:30 p.m. et citi's 2024 virtual oncology leadership summit, thursday, february 22nd at 3:00 p.m. et a live webcast will be available via the investors and media section of 2seventy bi.

Cambridge, mass.--(business wire)--2seventy bio, inc. (nasdaq: tsvt), announced today that it is transforming the company to focus exclusively on the commercialization and development of abecma (idecabtagene vicleucel), its bcma-targeted car t therapy for multiple myeloma. the actions announced today follow an extensive evaluation of the company's business and strategic alternatives by its board of directors. as a result of this strategic re-alignment, the company expects annual savings of appr.

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.

Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for their blood cancer treatment, Abecma, next month as originally planned.

Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential approval of earlier use of a cancer therapy.

2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.